WebMay 3, 2024 · Primary Purpose: Treatment: Official Title: To Evaluate the Efficacy and Safety of High-Dose Almonertinib Versus Osimertinib in the Second-Line Treatment of Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: a Multicenter, Randomized Controlled, Double-Blind Clinical Trial: Estimated Study Start Date : June 1, … Web1 day ago · Statistical significance was reached in the primary end point of time to alleviation of all influenza symptoms between both ZX-7101A treated groups relative to the placebo group (p-value: 0.008 ...
Influence of germline variations in drug transporters ABCB1 and …
WebMay 30, 2024 · Leptomeningeal metastasis (LM) is a complication of deeper concerns due … WebAug 27, 2024 · Local therapies performed to the oligo-residual tumor lesions or primary lung site before Osimertinib treatment failure were considered as LCT. Of 108 patients recruited, first-line and second-line Osimertinib were administered in 25 and 83 patients, respectively, while LCT was performed in 14 patients. sykes farm tea room
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR ...
WebMethods. Patients who started treatment with osimertinib for EGFRm+ NSCLC between November 2014 and June 2024 were included in this retrospective observational multicentre cohort study.For patients with baseline CNS metastases, the primary endpoint was CNS progression-free survival (CNS-PFS; time from osimertinib start until CNS disease … WebIntroduction Osimertinib, a third-generation epidermal growth factor receptor (EGFR) … WebFeb 24, 2024 · Patients were treated with T-DM1 3.6 mg/kg (intravenously) every 3 weeks and osimertinib 80 mg once a day. Primary end points were objective response rate (ORR) at 12 weeks and safety. Responses were assessed every 6 weeks (Response Evaluation Criteria in Solid Tumors 1.1). sykes fell cheese